United States Public Health Service Tuberculosis Therapy Trial 21: preliminary results of an evaluation of a combination tablet of isoniazid, rifampin and pyrazinamide.
Geiter
L J
LJ
Division of Tuberculosis Control, Centers for Disease Control, Atlanta, Georgia 30333.
O'Brien
R J
RJ
Combs
D L
DL
Snider
D E
DE
D002986:Clinical Trials as Topic; D004338:Drug Combinations; D005260:Female; D006801:Humans; D007538:Isoniazid / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D010349:Patient Compliance; D011718:Pyrazinamide / Q000009:adverse effects / Q000627:therapeutic use*; D011897:Random Allocation; D012293:Rifampin / Q000009:adverse effects / Q000627:therapeutic use*; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
D004338:Drug Combinations; D011718:Pyrazinamide; D007538:Isoniazid; D012293:Rifampin